보고서 요약(국문)

개요
전 세계 사지대근육병 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 사지대근육병 치료 시장은 여러 요인의 영향으로 상당한 성장과 변화를 경험해 왔습니다. 사지대근육병은 근육 손실과 약화(근육 위축)를 유발하는 광범위한 유전 질환입니다. 이 질환은 상염색체 열성 유전으로 발병하며, 일반적으로 부모 양쪽 모두에서 결함이 있는(기능하지 않는) 유전자를 물려받아야 합니다.
특히 개발도상국을 중심으로 한 정부 투자와 연구는 유전자 치료 또는 코르티코스테로이드와 같은 새로운 치료법을 위한 첨단 기술 활용을 지속적으로 촉진하고, 1형 및 2형 사지대근육병에 대한 치료를 활성화하여 전 세계 사지대근육병 치료 시장의 성장을 견인할 것입니다.

시장 동향: 성장 동력 및 제약 요인
협력 증가 및 규제 승인
선진국들은 높은 투자, 소득 수준, 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서 연구 활동 증가로 인해 사지대 근육병 치료에 대한 수요가 크게 증가하고 있습니다. 다양한 국가 간의 협력, 인수, 라이선스 계약 및 기술 발전은 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2023년 7월 12일, 미션 크리티컬 시스템용 인공지능 개발업체인 유럽의 탈레스(Thales)와 희귀 유전 질환 유전자 치료 개발 및 연구 분야의 혁신 기업이자 선도 기업인 제네톤(Genethon)은 유전자 치료 분야의 생물 생산을 향상시키는 최초의 효과적인 디지털 모델을 구축하기 위해 전문성을 결합했습니다. 유전자 치료제 개발은 매우 어렵고 복잡하며 비용이 많이 들고 시간이 오래 걸리는 과정입니다. 생산 비용과 시간을 줄이는 것은 중요한 과제입니다.

또한, 바이엘 AG의 완전 자회사이자 독립적으로 운영되는 아스클레피오스 바이오파마슈티컬(Asklepios BioPharmaceutical, Inc.)에 따르면, 2023년 2월 16일 사지대근육병증(LGMD) 치료제 AB-1003(LION-101이라고도 함)이 유럽 위원회(EC)로부터 희귀의약품 지정을 받았습니다.
더불어, 사지대근육병증에 대한 새로운 의약품 및 솔루션의 활용이 증가하고 있습니다. 근육병증 환자 수 증가와 여러 약물의 사용 증가, 그리고 혁신적인 제품 개발 연구는 사지대근육병증 치료 시장 성장을 이끄는 주요 요인이 될 것입니다.
치료와 관련된 부작용
유전자 치료법은 아직 비교적 새로운 형태의 의학이지만, 광범위한 질병을 치료할 수 있는 잠재력을 가지고 있습니다. 특정 암, 알레르기 반응, 주사가 필요한 경우 장기 또는 조직 손상 등이 잠재적 위험의 예입니다. 최근의 발전으로 유전자 치료법은 현재 더 안전해졌습니다. 초기 연구에서는 유전자 치료와 관련된 독성, 염증, 악성 종양 등 매우 심각한 건강 위험이 있는 것으로 나타났습니다.
세그먼트 분석
전 세계 사지대근육병 치료 시장은 유형, 치료법, 최종 사용자 및 지역별로 세분화됩니다.
사지대근육병 2형(LGMD2A) 부문은 시장 점유율의 약 56%를 차지했습니다.
칼페인병증(Calpainopathy), 또는 사지대근육병 2A형은 CAPN3 유전자 변이에 의해 발생합니다. 사지대근육병 환자의 약 30%가 2A형이며, 이는 가장 흔한 유형입니다. 디스페를린병증(Dysferlinopathy), 또는 사지대근육병 2B형은 DYSF 유전자 변이에 의해 발생합니다.
LGMD2A의 초기 증상으로는 어깨, 고관절, 허벅지 근육의 약화와 위축(근육량 감소)이 흔히 나타납니다. 다리 증상은 어깨와 팔 증상보다 먼저 나타나며, 이러한 약화는 일반적으로 신체의 양쪽에 동일하게 영향을 미칩니다.

2023년 9월 19일, α-사르코글리칸(SGCG)과 관련된 2C/R5형 사지대근육병증(LGMD2C/R5) 유전자 치료제인 ATA-200이 신경근육 질환을 표적으로 하는 차세대 유전자 치료제 개발을 전문으로 하는 생명공학 기업 아타미오 테라퓨틱스(Atamyo Therapeutics)에 의해 유럽에서 임상시험 허가 신청(CTA)이 제출되었습니다. 또한, 아타미오 테라퓨틱스는 ATA-200이 프랑스 공공 프로그램인 Bpifrance의 France 2030으로부터 최대 800만 유로(860만 달러)의 비희석성 자금 지원을 승인받았다고 밝혔습니다. 이 자금은 임상시험 및 산업 개발 프로젝트를 지원하는 데 사용될 예정입니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 39%를 차지했습니다.
의료 분야에서 사지대근육병증 치료에 대한 수요가 증가함에 따라 북미 지역 제조업체들은 사업 확장의 기회를 갖고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 사지대근육병증 치료제에 대한 수요가 증가하고 있습니다.
의료비 지출 증가, 기술 발전, 다양한 질병에 대한 여러 종류의 약물 개발, 그리고 이 지역 전반에 걸친 바이오제약 또는 생명공학 기업의 설립 증가는 사지대근육병증 치료제 시장 점유율 성장에 기여하고 있습니다. 다양한 신규 치료법에 대한 인식이 높아짐에 따라 이 지역의 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계에서 주도적인 위치를 차지하고 있음을 보여줍니다.
북미는 미국을 중심으로 세계 사지대근육병증 치료제 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 첨단 기술 발전에 대한 집중은 미국 내 사지대근육병 치료제 수요를 촉진했으며, 미국 정부는 다양한 정책이나 수술 절차를 적극적으로 시행하여 이러한 치료제에 대한 수요를 자극해 왔습니다.

COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 사지대근육병증 치료제 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄 조치, 공급망 차질, 경제 활동 위축에 직면하면서 코르티코스테로이드 또는 소분자 약물을 주요 소비하는 제약 부문은 큰 타격을 입었습니다. 2020년 초부터 시작된 팬데믹으로 인한 광범위한 봉쇄와 제한 조치는 전 세계 여러 사업에 영향을 미쳤습니다.
주요 의료 및 생명공학 산업은 활동을 중단하고 COVID-19 관리에 집중하면서 사지대근육병증 치료제 수요가 급감했습니다. 그러나 현재 여러 연구가 재개되었고 기업들은 제품 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로 팬데믹이 전 세계 사지대근육병증 치료제 시장에 미치는 영향은 비교적 완만할 것으로 예상되며, 새로운 치료법에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.

주요 개발 사항
• 바이엘 AG의 자회사로 완전히 소유 및 운영되는 유전자 치료 회사인 아스클레피오스 바이오파마슈티컬(Asklepios BioPharmaceutical, Inc.)에 따르면, 2023년 8월 3일, 사지대 근육 dystrophy 2I/R9형(LGMD2I/R9) 환자를 대상으로 하는 LION-CS101 1/2상 연구의 첫 번째 참가자에게 투약이 완료되었습니다. 현재 연구 중인 새로운 FKRP 대체 유전자 치료제는 AB-1003(LION-101이라고도 함)입니다.

• 2023년 6월 22일, 미국 식품의약국(FDA)은 아데노 관련 바이러스 기반 유전자 치료제인 델란디스트로겐 목세파르보벡-로클(ELEVIDYS)의 승인을 신속 처리했습니다. 희귀 질환 정밀 유전자 치료 분야의 선구자인 사렙타 테라퓨틱스(Sarepta Therapeutics, Inc.)에 따르면, ELEVIDYS는 뒤센 근디스트로피(DMD) 유전자 변이가 확인된 보행 가능한 소아 및 청소년 DMD 환자의 치료를 위한 치료제입니다. ELEVIDYS 치료 환자에게서 관찰된 ELEVIDYS 마이크로-디스트로핀 수치를 기반으로 신속 승인이 이루어졌습니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 주빌런트 카디스타 파마슈티컬스(Jubilant Cadista Pharmaceuticals Inc.), 사렙타 테라퓨틱스(Sarepta Therapeutics, Inc.), ML 바이오 솔루션(ML Bio Solutions), 제네톤(Genethon), 아스클레피오스 바이오파마슈티컬(Asklepios BioPharmaceutical, Inc.), 아타미오 테라퓨틱스(Atamyo Therapeutics), 비타 테라퓨틱스(Vita Therapeutics, Inc.), 에지와이즈 테라퓨틱스(Edgewise Therapeutics), 브리지바이오(BridgeBio Inc.), 한사 바이오파마(Hansa Biopharma) 등이 있습니다. 보고서 구매 이유

• 유형, 치료법, 최종 사용자 및 지역별 글로벌 사지대 근육 dystrophy 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 사지대 근육 dystrophy 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 Excel 파일로 제공합니다.

글로벌 사지대 근육 dystrophy 치료 시장 보고서는 약 61개의 표, 57개의 그림, 186페이지로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global limb girdle muscular dystrophy treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global limb girdle muscular dystrophy treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A vast set of hereditary illnesses known as limb-girdle muscular dystrophies cause muscle loss and weakening (muscular dystrophy). To develop the illness (autosomal recessive inheritance), often both parents have to pass on the defective (inoperative) gene.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced technology for novel treatments such as gene therapy or corticosteroids for limb-girdle muscular dystrophy type 1 and type 2 and boost the global limb girdle muscular dystrophy treatment market.
Market Dynamics: Drivers & Restraints
Growing collaborations and regulatory approvals
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for limb girdle muscular dystrophy treatment owing to the rising research. Various collaborations, acquisitions and license agreement with technological advancements among different countries will be a crucial factor driving the growth of the market.
On July 12, 2023, in order to create the first of its kind effective digital models for enhancing bioproduction produces in the area of gene therapy, Thales, a European developer in artificial intelligence for mission-critical systems, and Genethon, an innovator and leader in genetic therapy development and research for rare genetic diseases, are bringing together their expertise. Gene therapy treatment development is a very difficult, intricate, expensive, and time-consuming procedure. The reduction of production costs and time represents a significant challenge.
Additionally, on February 16, 2023, the limb-girdle muscular dystrophy (LGMD) medicine AB-1003 (also known as LION-101) has been given orphan drug designation by the European Commission (EC), according to Asklepios BioPharmaceutical, Inc., a fully owned and independently run subsidiary of Bayer AG.
Furthermore, the rising utilization of novel medicines and solutions for limb girdle muscular dystrophy. Rising muscular dystrophy cases and increasing utilization of several drugs along with research for innovative product development will be a major factor driving the growth of the limb girdle muscular dystrophy treatment market.
Side effects associated with the therapy
Although they are still relatively new forms of medicine, genetic treatments offer the potential to treat a wide range of illnesses. Certain cancers, allergic reactions, or organ or tissue damage if an injection is involved are examples of potential dangers. Genetic medicines are currently more safer owing to recent developments. Early research indicated very substantial health hazards associated with gene therapy, including toxicity, inflammation, and malignancy.
Segment Analysis
The global limb girdle muscular dystrophy treatment market is segmented based on type, treatment, end user and region.
Limb-girdle muscular dystrophy type 2 type segment accounted for approximately 56% of market share
Calpainopathy, also known as limb-girdle muscular dystrophy form 2A, is brought on by CAPN3 gene mutations. About 30% of cases of limb-girdle muscular dystrophy are Type 2A, which is also the most prevalent type. Dysferlinopathy is also known as limb-girdle muscular dystrophy form 2B and is brought on by DYSF gene mutations.
Initial symptoms of LGMD2A include frequently weakness and wastage (loss of muscular mass) in the shoulder, hip, and thigh muscles. Leg involvement is apparent earlier shoulder and arm involvement, and this weakness typically affects each side of the body equally.
On September 19, 2023, ATA-200, a gene therapy for type 2C/R5 limb-girdle muscular dystrophy (LGMD2C/R5) that is related to -sarcoglycan (SGCG), was the subject of a Clinical Trial Application (CTA) filed in Europe by Atamyo Therapeutics, a biotechnology company specializing in the creation of new-generation gene treatments targeting neuromuscular diseases. The business also said that ATA-200 has been approved for non-dilutive funding from France 2030, a public program run by Bpifrance, in the amount of up to €8 million ($8.6 million), to support their clinical trial and industrial development projects.
Geographical Penetration
North America accounted for around 39% of market share in 2022
Due to the rising need for limb girdle muscular dystrophy treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for limb girdle muscular dystrophy treatment.
Increasing expenditure on healthcare, advancement of technologies and different types of medications for several diseases, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of limb girdle muscular dystrophy treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments. The aforementioned elements attest to North America's hegemonic position in the world.
North America continues to be a key player in the global limb girdle muscular dystrophy treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for limb girdle muscle medications in the United States have been proactive in executing several initiatives or surgical procedures, stimulating these medications demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global limb girdle muscular dystrophy treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of corticosteroid or small molecule, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for limb girdle muscular dystrophy treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global limb girdle muscular dystrophy treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for novel treatments.
Key Developments
• On August 3, 2023, the initial participant in the Phase 1 / Phase 2 LION-CS101 research study for people having limb-girdle muscular dystrophy subtype 2I/R9 (LGMD2I/R9) was recently dosed, according to Asklepios BioPharmaceutical, Inc., a genetic therapy company that is entirely owned and independently run as a subsidiary of Bayer AG. A brand-new FKRP replacement gene therapy under research is called AB-1003 (also referred to as LION-101).
• On June 22, 2023, the FDA accelerated the authorization of delandistrogene moxeparvovec-rokl (ELEVIDYS), an adeno-associated virus-based gene therapy, which is intended for the management of ambulatory children and adolescents with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene, according to Sarepta Therapeutics, Inc., the pioneer in precision genetic therapy for rare diseases. Based on the levels of ELEVIDYS micro-dystrophin seen in ELEVIDYS-treated patients, this indication was given accelerated approval.
Competitive Landscape
The major global players in the market include Jubilant Cadista Pharmaceuticals Inc., Sarepta Therapeutics, Inc., ML Bio Solutions, Genethon, Asklepios BioPharmaceutical, Inc., Atamyo Therapeutics, Vita Therapeutics, Inc., Edgewise Therapeutics, BridgeBio Inc. and Hansa Biopharma.
Why Purchase the Report?
• To visualize the global limb girdle muscular dystrophy treatment market segmentation based on type, treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of limb girdle muscular dystrophy treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global limb girdle muscular dystrophy treatment market report would provide approximately 61 tables, 57 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing collaborations and regulatory approvals
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the therapy
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Limb-girdle Muscular Dystrophy Type 1*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Limb-girdle Muscular Dystrophy Type 2
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Medications *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Corticosteroids
8.2.3.1. Prednisone
8.2.3.2. Deflazacort (Emflaza)
8.2.4. Small Molecule
8.2.4.1. Ribitol (BBP-418)
8.3. Gene Therapy
8.4. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Jubilant Cadista Pharmaceuticals Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Sarepta Therapeutics, Inc.
12.3. ML Bio Solutions
12.4. Genethon
12.5. Asklepios BioPharmaceutical, Inc.
12.6. Atamyo Therapeutics
12.7. Vita Therapeutics, Inc.
12.8. Edgewise Therapeutics
12.9. BridgeBio Inc.
12.10. Hansa Biopharma
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Jubilant Cadista Pharmaceuticals Inc., 4. Key Developments, Sarepta Therapeutics, Inc., ML Bio Solutions, Genethon, Asklepios BioPharmaceutical, Inc., Atamyo Therapeutics, Vita Therapeutics, Inc., Edgewise Therapeutics, BridgeBio Inc., Hansa Biopharma

표 목록 (Tables)

List of Tables

Table 1 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 7 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 9 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 11 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Limb Girdle Muscular Dystrophy Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 14 North America Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 15 North America Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 16 North America Limb Girdle Muscular Dystrophy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 18 South America Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 19 South America Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 20 South America Limb Girdle Muscular Dystrophy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 22 Europe Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 23 Europe Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 24 Europe Limb Girdle Muscular Dystrophy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Limb Girdle Muscular Dystrophy Treatment Market Value, By Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Limb Girdle Muscular Dystrophy Treatment Market Value, By Treatment, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Limb Girdle Muscular Dystrophy Treatment Market Value, By End User, 2021-2030 (US$ Million)

Table 32 Jubilant Cadista Pharmaceuticals Inc.: Overview

Table 33 Jubilant Cadista Pharmaceuticals Inc.: Product Portfolio

Table 34 Jubilant Cadista Pharmaceuticals Inc.: Key Developments

Table 35 Sarepta Therapeutics, Inc.: Overview

Table 36 Sarepta Therapeutics, Inc.: Product Portfolio

Table 37 Sarepta Therapeutics, Inc.: Key Developments

Table 38 ML Bio Solutions: Overview

Table 39 ML Bio Solutions: Product Portfolio

Table 40 ML Bio Solutions: Key Developments

Table 41 Genethon: Overview

Table 42 Genethon: Product Portfolio

Table 43 Genethon: Key Developments

Table 44 Asklepios BioPharmaceutical, Inc.: Overview

Table 45 Asklepios BioPharmaceutical, Inc.: Product Portfolio

Table 46 Asklepios BioPharmaceutical, Inc.: Key Developments

Table 47 Atamyo Therapeutics: Overview

Table 48 Atamyo Therapeutics: Product Portfolio

Table 49 Atamyo Therapeutics: Key Developments

Table 50 Vita Therapeutics, Inc.: Overview

Table 51 Vita Therapeutics, Inc.: Product Portfolio

Table 52 Vita Therapeutics, Inc.: Key Developments

Table 53 Edgewise Therapeutics: Overview

Table 54 Edgewise Therapeutics: Product Portfolio

Table 55 Edgewise Therapeutics: Key Developments

Table 56 BridgeBio Inc.: Overview

Table 57 BridgeBio Inc.: Product Portfolio

Table 58 BridgeBio Inc.: Key Developments

Table 59 Hansa Biopharma: Overview

Table 60 Hansa Biopharma: Product Portfolio

Table 61 Hansa Biopharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Limb Girdle Muscular Dystrophy Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Limb Girdle Muscular Dystrophy Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 4 Global Limb Girdle Muscular Dystrophy Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 5 Global Limb Girdle Muscular Dystrophy Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Limb Girdle Muscular Dystrophy Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Limb-girdle Muscular Dystrophy Type 1 Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Limb-girdle Muscular Dystrophy Type 2 Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Global Limb Girdle Muscular Dystrophy Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 10 Medications Treatment in Global Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Gene Therapy Treatment in Global Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Others Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Global Limb Girdle Muscular Dystrophy Treatment Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 14 Hospitals End User in Global Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Ambulatory Surgical Centers End User in Global Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Others End User in Global Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 17 Global Limb Girdle Muscular Dystrophy Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 18 North America Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Europe Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 21 South America Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Middle East and Africa Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 North America Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 North America Limb Girdle Muscular Dystrophy Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 25 North America Limb Girdle Muscular Dystrophy Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 26 North America Limb Girdle Muscular Dystrophy Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 27 North America Limb Girdle Muscular Dystrophy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 28 South America Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 29 South America Limb Girdle Muscular Dystrophy Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 30 South America Limb Girdle Muscular Dystrophy Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 31 South America Limb Girdle Muscular Dystrophy Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 32 South America Limb Girdle Muscular Dystrophy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 33 Europe Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 34 Europe Limb Girdle Muscular Dystrophy Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 35 Europe Limb Girdle Muscular Dystrophy Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 36 Europe Limb Girdle Muscular Dystrophy Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 37 Europe Limb Girdle Muscular Dystrophy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 38 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 40 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 41 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 42 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 43 Asia-Pacific Limb Girdle Muscular Dystrophy Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 44 Middle East & Africa Limb Girdle Muscular Dystrophy Treatment Market Value, 2021-2030 (US$ Million)

Figure 45 Middle East & Africa Limb Girdle Muscular Dystrophy Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 46 Middle East & Africa Limb Girdle Muscular Dystrophy Treatment Market Share, By Treatment, 2022 & 2030 (%)

Figure 47 Middle East & Africa Limb Girdle Muscular Dystrophy Treatment Market Share, By End User, 2022 & 2030 (%)

Figure 48 Jubilant Cadista Pharmaceuticals Inc.: Financials

Figure 49 Sarepta Therapeutics, Inc.: Financials

Figure 50 ML Bio Solutions: Financials

Figure 51 Genethon: Financials

Figure 52 Asklepios BioPharmaceutical, Inc.: Financials

Figure 53 Atamyo Therapeutics: Financials

Figure 54 Vita Therapeutics, Inc.: Financials

Figure 55 Edgewise Therapeutics: Financials

Figure 56 BridgeBio Inc.: Financials

Figure 57 Hansa Biopharma: Financials

세계 사지대 근육 dystrophy 치료 시장 – 2023-2030

Global Limb Girdle Muscular Dystrophy Treatment Market -2023-2030